Cytokinetics, Incorporated
US ˙ NasdaqGS ˙ US23282W6057

Introduction

This page provides a comprehensive analysis of the known insider trading history of James H Sabry. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate James H Sabry has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CYTK / Cytokinetics, Incorporated Director 145,521
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James H Sabry. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CYTK / Cytokinetics, Incorporated - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYTK / Cytokinetics, Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYTK / Cytokinetics, Incorporated Insider Trades
Insider Sales CYTK / Cytokinetics, Incorporated - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYTK / Cytokinetics, Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2009-11-16 CYTK Sabry James H 100 3.3800 100 3.3800 338 276 12.48 910 269.23
2009-11-16 CYTK Sabry James H 541 3.3900 541 3.3900 1,834
2009-11-16 CYTK Sabry James H 6,255 3.4000 6,255 3.4000 21,267
2009-11-16 CYTK Sabry James H 8,498 3.4100 8,498 3.4100 28,978
2009-11-16 CYTK Sabry James H 400 3.4150 400 3.4150 1,366
2009-11-16 CYTK Sabry James H 31,306 3.4200 31,306 3.4200 107,067
2009-11-16 CYTK Sabry James H 8,594 3.4300 8,594 3.4300 29,477
2009-11-16 CYTK Sabry James H 5,066 3.4400 5,066 3.4400 17,427
2009-11-16 CYTK Sabry James H 5,240 3.4500 5,240 3.4500 18,078
2009-11-13 CYTK Sabry James H 9,060 3.3400 9,060 3.3400 30,260
2009-11-13 CYTK Sabry James H 19,500 3.3500 19,500 3.3500 65,325
2009-11-13 CYTK Sabry James H 1,700 3.3600 1,700 3.3600 5,712
2009-11-13 CYTK Sabry James H 10,440 3.3400 10,440 3.3400 34,870
2009-11-13 CYTK Sabry James H 23,500 3.3500 23,500 3.3500 78,725
2009-11-13 CYTK Sabry James H 1,504 3.3600 1,504 3.3600 5,053
2009-11-13 CYTK Sabry James H 496 3.3700 496 3.3700 1,672

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYTK / Cytokinetics, Incorporated Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by James H Sabry as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -15,733 145,521 -9.76
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Incentive Stock Option (right to buy)
M - Exercise -50,267 33,066 -60.32
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -5,240 0 -100.00 3.45 -18,078
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -5,066 5,240 -49.16 3.44 -17,427 18,026
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -8,594 10,306 -45.47 3.43 -29,477 35,350
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -31,306 18,900 -62.36 3.42 -107,067 64,638
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -400 50,206 -0.79 3.42 -1,366 171,453
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -8,498 50,606 -14.38 3.41 -28,978 172,566
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -6,255 59,104 -9.57 3.40 -21,267 200,954
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -541 65,359 -0.82 3.39 -1,834 221,567
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
M - Exercise 15,733 65,900 31.36 1.20 18,880 79,080
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -100 50,167 -0.20 3.38 -338 169,564
2009-11-17 2009-11-16 4 CYTK CYTOKINETICS INC
Common Stock
M - Exercise 50,267 50,267 1.20 60,320 60,320
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Incentive Stock Option (right to buy)
M - Exercise -35,940 136,473 -20.85
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -496 0 -100.00 3.37 -1,672
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -1,504 496 -75.20 3.36 -5,053 1,667
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -23,500 2,000 -92.16 3.35 -78,725 6,700
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -10,440 25,500 -29.05 3.34 -34,870 85,170
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
M - Exercise 35,940 35,940 0.58 20,845 20,845
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -1,700 0 -100.00 3.36 -5,712
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -19,500 1,700 -91.98 3.35 -65,325 5,695
2009-11-17 2009-11-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -9,060 21,200 -29.94 3.34 -30,260 70,808
2009-11-17 2009-09-17 4 CYTK CYTOKINETICS INC
Common Stock
G - Gift -2,000 30,260 -6.20
2004-04-28 3 CYTK CYTOKINETICS INC
Common Stock
250,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)